|
May 14
|
Benitec Biopharma Releases Third Quarter 2025 Financial Results
|
|
May 5
|
Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why
|
|
May 2
|
Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year?
|
|
Apr 16
|
Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?
|
|
Mar 12
|
Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?
|
|
Feb 20
|
Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know
|
|
Oct 1
|
Suvretta Capital Management's Strategic Acquisition in Benitec Biopharma Inc
|
|
Sep 28
|
Benitec Biopharma (NASDAQ:BNTC) Is In A Good Position To Deliver On Growth Plans
|
|
Sep 26
|
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
|
|
Sep 18
|
Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society
|
|
Sep 17
|
Benitec Biopharma CEO to Participate in OPMD Awareness Day Webinar
|
|
May 13
|
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
|
|
Apr 18
|
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
|
|
Apr 18
|
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
|
|
Apr 9
|
Benitec Biopharma to Host Virtual R&D Day to Discuss BB-301 Clinical Program in Oculopharyngeal Muscular Dystrophy on April 18, 2024
|
|
Mar 24
|
11 Best ASX Stocks To Buy Now
|
|
Nov 30
|
Benitec Biopharma Announces First Subject Dosed in Phase 1b/2a Clinical Trial for Gene Therapy Candidate BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy
|
|
Nov 30
|
Here's Why Benitec Biopharma Inc.'s (NASDAQ:BNTC) CEO Compensation Is The Least Of Shareholders Concerns
|
|
Aug 11
|
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering
|
|
Aug 9
|
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
|